Picture of Oxford BioMedica logo

OXB Oxford BioMedica Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+11.83%
3m-2.26%
6m-30.84%
1yr-58.76%
Volume Change (%)
10d/3m+54.83%
Price vs... (%)
52w High-58.52%
50d MA+7.75%
200d MA-27.04%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-17.79%
Return on Equity-31.27%
Operating Margin-51.93%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Oxford BioMedica EPS forecast chart

Profile Summary

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
September 20th, 1996
Public Since
November 15th, 1996
No. of Employees
891
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
99,957,395

OXB Share Price Performance

Upcoming Events for OXB

Full Year 2023 Oxford Biomedica PLC Earnings Release

Oxford BioMedica PLC Annual Shareholders Meeting

Half Year 2024 Oxford Biomedica PLC Earnings Release

Similar to OXB

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

Picture of Batm Advanced Communications logo

Batm Advanced Communications

gb flag iconLondon Stock Exchange

FAQ